PTGX Protagonist Therapeutics, Inc: institutional ownership and insider trading
371 funds reported holding $10.2B of Protagonist Therapeutics, Inc in their latest 13F filings; in Q2 2026 funds net bought $595M, with 62 new positions and 36 funds selling out; over the last 12 months insiders bought $0 and sold $87.7M on the open market; over its last four quarters it reported revenue of $282M and net income of $82.9M.
PTGX revenue and earnings
- Quarter ended Jun 30, 2026: revenue $213M, net income $163M, EPS 2.29
- Quarter ended Mar 31, 2026: revenue $56.4M, net income $3.78M, EPS 0.05
- Quarter ended Dec 31, 2025: revenue $7.44M, net income −$44.4M, EPS -0.69
- Quarter ended Sep 30, 2025: revenue $4.71M, net income −$39.3M, EPS -0.62
Famous investors holding PTGX
- Stanley Druckenmiller (Duquesne Family Office): $25.6M, 0.5% of the portfolio
- Ken Griffin (Citadel Advisors): $5.61M, 0.0% of the portfolio
- Ray Dalio (Bridgewater Associates): $1.14M, 0.0% of the portfolio
Largest institutional holders of PTGX
- BlackRock, Inc. (BLK) — $1.26B
- FARALLON CAPITAL MANAGEMENT, L.L.C. — $778M
- RTW INVESTMENTS, LP — $620M
- VANGUARD GROUP INC — $473M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $445M
- WELLINGTON MANAGEMENT GROUP LLP — $419M
- UBS Group AG (UBS) — $417M
- STATE STREET CORP (STT, STT-PG) — $407M
- VANGUARD CAPITAL MANAGEMENT LLC — $350M
- JANUS HENDERSON GROUP PLC (JHG) — $305M
Recent PTGX insider trades
- Sep 30, 2026: Ali Asif sold 58,629 shares ($8.31M)
- Sep 10, 2026: Patel Dinesh V Ph D sold 125,000 shares ($18.2M)
- Aug 11, 2026: Patel Dinesh V Ph D sold 100,000 shares ($14.9M)
- Jun 23, 2026: Waddill William D. sold 9,000 shares ($1.06M)
5%+ owners
- Farallon Capital Management, L.L.C.: 10.0% (Schedule 13G/A, filed Aug 13, 2026)
- Vanguard Portfolio Management: 5.5% (Schedule 13G, filed Apr 29, 2026)
- STATE STREET CORPORATION: 5.2% (Schedule 13G, filed Aug 7, 2026)
- Vanguard Capital Management: 5.1% (Schedule 13G, filed Apr 30, 2026)
Who owns the most PTGX stock?
The largest institutional holders of Protagonist Therapeutics, Inc in the latest 13F filings are BlackRock, Inc. (BLK) ($1.26B), FARALLON CAPITAL MANAGEMENT, L.L.C. ($778M), RTW INVESTMENTS, LP ($620M).
Are insiders buying or selling PTGX?
Over the last 12 months insiders bought $0 and sold $87.7M of Protagonist Therapeutics, Inc stock on the open market (SEC Form 4).
Which famous investors own PTGX?
Stanley Druckenmiller, Ken Griffin, Ray Dalio.
What was PTGX's revenue last quarter?
Protagonist Therapeutics, Inc reported revenue of $213M for the quarter ended June 30, 2026, with net income of $163M.
Which ETFs hold PTGX?
149 ETFs and mutual funds hold it among their top 100 positions, including IJR, IWM, VGHAX, VEXPX.